浏览全部资源
扫码关注微信
中山大学孙逸仙纪念医院心血管内科,广东 广州 510120
WEI Yu-lin; E-mail: weiyulin@mail.sysu.edu.cn
Published:20 November 2023,
Received:26 August 2023,
扫 描 看 全 文
冯日清,蒙媛丽,刘英梅等.左室长轴应变在鉴别心脏淀粉样变与高血压左室肥厚中的应用价值[J].中山大学学报(医学科学版),2023,44(06):1046-1052.
FENG Ri-qing,MENG Yuan-li,LIU Ying-mei,et al.Left Ventricle Longitudinal Strain Parameters Are Effective for Differentiating Cardiac Amyloidosis from Primary Hypertensive Left Ventricular Hypertrophy[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(06):1046-1052.
冯日清,蒙媛丽,刘英梅等.左室长轴应变在鉴别心脏淀粉样变与高血压左室肥厚中的应用价值[J].中山大学学报(医学科学版),2023,44(06):1046-1052. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0620.
FENG Ri-qing,MENG Yuan-li,LIU Ying-mei,et al.Left Ventricle Longitudinal Strain Parameters Are Effective for Differentiating Cardiac Amyloidosis from Primary Hypertensive Left Ventricular Hypertrophy[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(06):1046-1052. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0620.
目的
2
本研究通过测定心脏淀粉样变(CA)患者与高血压左室肥厚(HLVH)患者的左室长轴心肌应变相关指标,并比较其差异性,进一步明确左室长轴心肌应变在CA患者早期诊断的价值。
方法
2
选出确诊为CA的患者41例,按患者既往是否合并原发性高血压分为CA并高血压组14例与单纯CA组27例,同时按性别、年龄及体表面积匹配HLVH患者20例及健康对照组20例。收集患者的临床资料,获取常规超声心动图指标包括室壁厚度(IVST、LVPWT、RWT)、心腔大小(LVEDD、LAVI)、收缩及舒张功能指标(LVEF、平均E/e'),以及左室长轴应变相关指标(GLS、RELAPS、EFSR)。比较4组研究对象的组内差异并进行组间两两比较,进一步测定LVEF保留时各超声心动图指标预测CA的敏感性与特异性。
结果
2
①超声心动图的常规指标中CA并高血压组和单纯CA组的LVEDD和LVEF均低于HLVH组;而CA并高血压组和单纯CA组的LVPWT、RWT及平均E/e'均高于HLVH组(
P
均<0.05)。②应变指标中CA并高血压组和单纯CA组的GLS绝对值最低,HLVH组次之,健康对照组最高;同时,CA并高血压组和单纯CA组的RELAPS与EFSR值最高,HLVH次之,健康对照组最低(
P
均<0.05)。CA并高血压组和单纯CA组的所有超声心动图指标差异均无统计学意义(
P
均>0.05)。③ROC曲线分析显示在LVEF保留时,GLS绝对值<14.35%或EFSR>4.28时可较好地鉴别CA和HLVH(AUC均>0.9,
P
均<0.05);GLS诊断的敏感性最高(100%),而EFSR诊断的特异性最高(95%)。
结论
2
无论CA是否合并高血压,与HLVH相比,其超声心动图的常规及应变指标上均有显著的差异;尤其是应变指标GLS和EFSR在左室肥厚并LVEF保留患者中预测CA的准确性更高。
Objective
2
To clarify the value of the left ventricular longitudinal strain(LVLS)parameters in patients with cardiac amyloidosis (CA) and primary hypertension with left ventricular hypertrophy (HLVH).
Methods
2
Forty-one patients confirmed with CA were selected and assigned to CA with hypertension group (
n
=14) and pure CA group (
n
=27) based on the initial diagnosis with or without hypertension. Twenty patients with primary hypertension-induced left ventricular hypertrophy (HLVH group) and twenty healthy controls were also selected, matching for gender, age, and body surface area. Clinical data, conventional echocardiography parameters were collected and LVLS parameters were measured. Within-group variations were compared among the four groups, and pairwise comparisons were conducted between groups. The sensitivity and specificity of each parameter in predicting CA were judged by the receiver operator characteristic (ROC) curvy in CA and HLVH patients with left ventricular ejection fraction (LVEF) preserved.
Results
2
Among the conventional echocardiography parameters, LVEF and left ventricular end-diastolic diameter (LVEDD) were lower in the CA with hypertension group and pure CA group compared with the higher values in the HLVH group and control group. Whereas, left ventricular posterior wall thickness (LVPWT), relative wall thickness (RWT), and average E/e' were higher in the two CA groups compared with the HLVH group (all
P
<0.05).Among the LVLS parameters, Global longitudinal strain (GLS) was the worst in the CA with hypertension group so as pure CA group, modest in the HLVH group, and highest in the control group. On the contrary, relative longitudinal strain and ejection fraction strain ratio (EFSR) were the highest in the CA with hypertension group so as to pure CA group, modest in the HLVH group, and lowest in the control group (all
P
<0.05). ROC analysis showed that when LVEF was preserved, the absolute value of GLS less than 14.35% and EFSR higher than 4.28 could effectively distinguish CA from HLVH (all AUCs>0.9,all
P
<0.05); meanwhile GLS showed high sensitivity(100%) and EFSR showed great specificity(95%). There were not statistically significance in any parameter between CA with hypertension group and pure CA group(all
P
>0.05).
Conclusion
2
Whether CA was complicated with hypertension or not, there were statistically significance among routine echocardiography and LVLS parameters compared with HLVH. In particular, GLS and EFSR are accurate in predicting CA in patients with myocardial hypertrophy and preserved LVEF.
心脏淀粉样变超声心动图心肌应变左室肥厚诊断
cardiac amyloidosisechocardiographyleft ventricular longitudinal strainleft ventricular hypertrophydiagnosis
Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versuslight-chain cardiac amyloidosis[J]. Circulation, 2014,129(18):1840-1849.
Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey[J]. Eur J Heart Fail, 2022,24(8):1377-1386.
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM /HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging [J].Circ Cardiovasc Imaging, 2021, 14(7):e000029.
Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guideline[J]. Hypertension, 2020,75(6):1334-1357.
Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiography examination in adults: recommendations from the American Society of echocardiography [J]. J Am Soc Echocardiogr, 2019, 32(1):1-64.
Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis[J]. Heart, 2012, 98:1442–1448.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].Circulation, 2022, 145(18):e895-e1032.
Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review[J]. JACC, 2019,73(22):2872-2891.
秦莹,孙筱璐,蒋文,等. 心肌淀粉样变在心肌肥厚患者中的检出率及临床特点与预后分析[J]. 中国循环杂志,2022,37(6):602-608.
Qin Y, Sun XL, Jiang W, et al. Clinical features and prognosis of cardiac amyloidosis in patients with myocardial hypertrophy[J]. Chin Circulat J,2022,37(6):602-608.
罗猛,刘洋,杨添添,等. 心肌淀粉样变性患者的临床特征及预后分析[J]. 中国循环杂志,2021,36(4):367-371.
Luo M, Liu Y, Yang TT, et al. Analysis of clinical features and prognosis of patients with cardiac amyloidosis[J]. Chin Circ J, 2021, 36(4):367-371.
Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium[J]. Adv Ther, 2015,32:920–928.
Maurer MS, Elliott P, Comenzo R, et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis[J]. Circulation, 2017(14):1357-1377.
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis[J]. N Engl J Med, 2018, 379(1):22-31.
Maurer MS, Schwartz JH, Gundapaneni B, et al. ATTR-ACT study investigators. tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J].N Engl J Med, 2018, 379(11):1007-1016.
Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee[J]. JACC, 2023,81(11):1076-1126.
Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center[J]. JACC, 1992,19(1): 43-47.
Manolis AS, Manolis AA, Manolis TA, et al. Cardiac amyloidosis: an underdiagnosed/underappreciated disease[J]. Eur J Intern Med,2019,67:1-13.
中华医学会心血管病分会心力衰竭学组. 转甲状腺素蛋白心脏淀粉样变诊断与治疗 中国专家共识[J]. 中华心血管病杂志,2021,49(4):324-332.
Heart Failure Group of Chinese Society of Cardiology. Chinese expert consensus on the diagnosis and treatment of transthyretin cardiac amyoidosis[J]. Chin J Cardiol, 2021, 49(4):324-332.
Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin amyloid variant[J]. Eur Heart J, 2012, 33:1120-1127.
Maurer MS HM, Grogan M, Dispenzieri A, et al. Genotype and phenotype of transthyretin cardiac amyloidosis in the United States: the transthyretin amyloid outcome survey (THAOS)[J]. JACC, 2016, 68:161-172.
González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths[J]. Eur Heart J,2017, 38(24):1895-1904.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of echocardiography and the European Association of Cardiovascular Imaging[J].J Am Soc Echocardiogr, 2016,29(4):277-314.
Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and Their Prognostic Roles[J].JACC Cardiovasc Imaging, 2019,12(5):823-833.
Milani P, Dispenzieri A, Scott CG, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis[J]. Circ Cardiovasc Imaging, 2018,11(5):e006588.
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases[J]. Eur Heart J, 2021, 42(16):1554-1568.
Bogunovic N, Farr M, Pirl L, et al. Multi-parametric speckle tracking analyses to characterize cardiac amyloidosis: a comparative study of systolic left ventricular longitudinal myocardial mechanics[J]. Heart Vessels, 2022,37(9):1526-1540.
Bravo PE, Fujikura K, Kijewski MF, et al. Relative apical sparing of myocardial longitudinal strain is explained by begional differences in total amyloid mass rather than the proportion of amyloid deposits[J]. JACC Cardiovasc Imaging, 2018,12(7Pt 1):1165-1173.
Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy[J]. Circ Cardiovasc Imaging, 2013,6:1066-1072.
Pagourelias ED, Duchenne J, Mirea O, et al.The Relation of ejection fraction and global longitudinal atrain in amyloidosis: implications for differential diagnosis[J]. JACC Cardiovasc Imaging, 2016,9(11):1358-1359.
Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters[J]. Circ Cardiovasc Imaging, 2017,10(3):e005588.
0
Views
9
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution